Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by mstrmndon Oct 17, 2021 1:17am
1076 Views
Post# 34014500

RE:RE:Time to Market for H2S Pipeline

RE:RE:Time to Market for H2S PipelineThis is what the company has reported in AGM and recent release.  There's no need to speculate anything otherwise, especially negative.  The market has not responded favourably, but make no mistake Antibe has a Phase 3 drug for post-operative pain coming and osteoarthritis is still on the table, with IBD next.

If you own Antibe, you own an entire drug platform including the patents to:
1) Hydrogen Sulfide + Naproxen
2) Hydrogen Sulfide + Ketoprofen
3) Hydrogen Sulfide + Aspirin
4) Hydrogen Sulfide + Mesalamine
5) Hydrogen Sulfide + Others TBD

ATE.TO is targetting medical sales for several indications in the multi-billions and requires a partner no doubt.  Hydrogen sulfide with an NSAID has superb medical properties and if they reduce the dose, we will just need to wait and see what the results will look like for post-operative pain, and other trials (indications) to come.  As per the original plan, we are in the acquisition period, who knows how big pharma will perceive this shift in analgesic markets, it's potential data and evidence for two big markets. 

At the end of the day, the science says, hydrogen sulfide + NSAID > NSAID alone, and that's worth a lot of money.

GLTA


Layth1990 wrote:

No one is spreading false information but you guys. Don't  give false hope to people. Atb 346 is out and the AME is not published because it is shi*t. They only mentioned about the 5x which triggered the stop and i gairantee you everyone has elevated LTE (x2, x3,x4).  If only a couple of people has elevated lte they would not move to acute pain which is 2 weeks treatment. the stomach protection has no meaning for two weeks since everyone can tolerate nsaids for two weeks with no issues. They want to go for acute pain but they don't have anything special.

Be realistic and logical ffs. Your comments are just making people average down for a sinking ship. Wait until they deplete the 60m. Whats next ? Another reverse split and financing ? If the science is worthy the platform would have been on the market by now.it has been 15 years probably. they cant prove it  and they know they have to keep on going because the whole platform is H2S. They don't want to shutdown and stop their paychecks. 



<< Previous
Bullboard Posts
Next >>